CERo Therapeutics Holdings, Inc.
CERO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1,163 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $268 | $269 | $581 |
| Gross Profit | $0 | -$268 | -$269 | $581 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $2,386 | $2,754 | $2,908 | $1,211 |
| G&A Expenses | $1,976 | $2,677 | $2,199 | $1,173 |
| SG&A Expenses | $1,976 | $2,677 | $2,199 | $1,173 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$707 | -$156 | $0 |
| Operating Expenses | $4,363 | $4,724 | $4,951 | $2,384 |
| Operating Income | -$4,363 | -$4,724 | -$4,951 | -$1,198 |
| % Margin | – | – | – | -103.1% |
| Other Income/Exp. Net | -$7,144 | -$694 | -$155 | $2,442 |
| Pre-Tax Income | -$11,506 | -$5,417 | -$5,106 | $1,244 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,506 | -$5,417 | -$5,106 | $1,244 |
| % Margin | – | – | – | 107% |
| EPS | -9.1 | -61.71 | -3.18 | 0.56 |
| % Growth | 85.3% | -1,840.6% | -667.9% | – |
| EPS Diluted | -9.1 | -61.71 | -3.18 | 0.56 |
| Weighted Avg Shares Out | 1,265 | 488 | 171 | 121 |
| Weighted Avg Shares Out Dil | 1,265 | 488 | 171 | 121 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $14 | $1 | -$4 |
| Interest Expense | $6 | $0 | $0 | -$27 |
| Depreciation & Amortization | $0 | $268 | $269 | $285 |
| EBITDA | -$4,363 | -$5,163 | -$4,837 | $1,546 |
| % Margin | – | – | – | 132.9% |